Pilot Protocol for Testing Fibrosis Regression
This pilot protocol is part of the Material-Directed Erasure research direction of the MME–TMP Programme. It provides a staged design for testing whether repurposed drugs can promote regression of established pulmonary fibrosis, using metformin as the reference candidate. The primary experiment compares lung collagen burden at the end of treatment with both a pretreatment baseline and a concurrent vehicle control. The baseline establishes whether collagen burden declined after treatment began. The vehicle comparison estimates whether the decline exceeded the change observed without the drug. The protocol defines separate GO / MODIFY / NO-GO criteria for three outcomes: net regression attributable to treatment, durability after verified drug clearance, and functional erasure of the matrix. The last stage tests whether an intervention changes a retained matrix property and reduces the cellular response attributable to that property. Version 0.1 is a study design and preregistration template. Dose, sampling windows, decision thresholds, and sample size are to be specified using feasibility data before the confirmatory experiment . Descrição em inglês para a versão 0.2 no Zenodo This proposed methodological protocol is part of the Material-Directed Erasure research direction of the MME–TMP Programme. It uses metformin as a reference candidate to test whether a repurposed drug can reduce collagen burden in established pulmonary fibrosis below the pretreatment baseline and beyond the change observed in a concurrent vehicle control. The protocol defines separate GO / MODIFY / NO-GO criteria for net fibrosis regression, durability after drug clearance, and functional erasure of the matrix. Functional erasure is assessed by testing whether treatment alters a retained matrix property and reduces the cellular response attributable to that property. Version 0.2 specifies total hydroxyproline per predefined anatomical unit as the primary outcome and identifies the matrix donor animal as the independent unit in functional assays. It also adds a pharmacokinetically informed washout plan with analytical verification in plasma and lung tissue, and updates the preregistration template accordingly. This protocol contains no original experimental data and is distributed under CC BY-SA 4.0. It builds on the programme’s related reviews of anthelmintic repurposing and evidence for regression with repurposed drugs.
Authors
- Christiano Gondim Moreira (ORCID: https://orcid.org/0009-0001-6133-7403)
Publication Details
- Journal
- Zenodo (CERN European Organization for Nuclear Research)
- Published
- 2026-11-16
- DOI
- https://doi.org/10.5281/zenodo.24294548
- Primary Topic
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Type
- preprint